ReP USP - Resultado da busca

Artigo de periodico
Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham- controlled, multicentre trial (2023)
Burkhardt, Gerrit; Kumpf, Ulrike; Crispin, Alexander; Goerigk, Stephan; Andre, Elisabeth; Plewnia, Christian; Brendel, Bettina; Fallgatter, Andreas; Langguth, Berthold; Brunoni, Andre Russowsky
Fonte: Lancet. Unidade: FM
Assuntos: ESTUDOS MULTICÊNTRICOS, DEPRESSÃO, ESTIMULAÇÃO MAGNÉTICA TRANSCRANIANA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BURKHARDT, Gerrit et al. Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham- controlled, multicentre trial. Lancet, v. 402, n. 10401, p. 545-554, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57346. Acesso em: 30 ago. 2024.
APA
Burkhardt, G., Kumpf, U., Crispin, A., Goerigk, S., Andre, E., Plewnia, C., et al. (2023). Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham- controlled, multicentre trial. Lancet, 402( 10401), 545-554. doi:10.1016/S0140-6736(23)00640-2
NLM
Burkhardt G, Kumpf U, Crispin A, Goerigk S, Andre E, Plewnia C, Brendel B, Fallgatter A, Langguth B, Brunoni AR. Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham- controlled, multicentre trial [Internet]. Lancet. 2023 ; 402( 10401): 545-554.[citado 2024 ago. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57346
Vancouver
Burkhardt G, Kumpf U, Crispin A, Goerigk S, Andre E, Plewnia C, Brendel B, Fallgatter A, Langguth B, Brunoni AR. Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham- controlled, multicentre trial [Internet]. Lancet. 2023 ; 402( 10401): 545-554.[citado 2024 ago. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57346
Artigo de periodico
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial (2023)
Heerspink, Hiddo J. L; Radhakrishnan, Jai; Alpers, Charles E; Barratt, Jonathan; Bieler, Stewart; Diva, Ulysses; Inrig, Jula; Komers, Radko; Mercer, Alex; Noronha, Irene de Lourdes
Fonte: Lancet. Unidade: FM
Assuntos: ALBUMINÚRIA, NEFROPATIAS, PROTEINÚRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEERSPINK, Hiddo J. L et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial. Lancet, v. 401, n. 10388, p. 1584-1594, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54593. Acesso em: 30 ago. 2024.
APA
Heerspink, H. J. L., Radhakrishnan, J., Alpers, C. E., Barratt, J., Bieler, S., Diva, U., et al. (2023). Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial. Lancet, 401( 10388), 1584-1594. doi:10.1016/S0140-6736(23)00569-X
NLM
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha I de L. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial [Internet]. Lancet. 2023 ; 401( 10388): 1584-1594.[citado 2024 ago. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54593
Vancouver
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha I de L. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial [Internet]. Lancet. 2023 ; 401( 10388): 1584-1594.[citado 2024 ago. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54593
Artigo de periodico
Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21 (2022)
Wang, Haidong; Paulson, Katherine R; Pease, Spencer A; Watson, Stefanie; Comfort, Haley; Zheng, Peng; Aravkin, Aleksandr Y; Bisignano, Catherine; Barber, Ryan M; Lotufo, Paulo Andrade
Fonte: Lancet. Unidade: FM
Assuntos: COVID-19, MORTALIDADE, PANDEMIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WANG, Haidong et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet, v. 399, n. 10334, p. 1513-1536, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(21)02796-3. Acesso em: 30 ago. 2024.
APA
Wang, H., Paulson, K. R., Pease, S. A., Watson, S., Comfort, H., Zheng, P., et al. (2022). Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet, 399( 10334), 1513-1536. doi:10.1016/S0140-6736(21)02796-3
NLM
Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, Aravkin AY, Bisignano C, Barber RM, Lotufo PA. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21 [Internet]. Lancet. 2022 ; 399( 10334): 1513-1536.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(21)02796-3
Vancouver
Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, Aravkin AY, Bisignano C, Barber RM, Lotufo PA. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21 [Internet]. Lancet. 2022 ; 399( 10334): 1513-1536.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(21)02796-3
Artigo de periodico
The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019 (2022)
Khanh Bao Tran; Lang, Justin J; Compton, Kelly; Xu, Rixing; Acheson, Alistair R; Henrikson, Hannah Jacqueline; Kocarnik, Jonathan M; Penberthy, Louise; Aali, Amirali; Alonso, Nivaldo
Fonte: Lancet. Unidade: FM
Assuntos: CONSENSO, NEOPLASIAS, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KHANH BAO TRAN, et al. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, v. 400, n. 10352, p. 563-591, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)01438-6. Acesso em: 30 ago. 2024.
APA
Khanh Bao Tran,, Lang, J. J., Compton, K., Xu, R., Acheson, A. R., Henrikson, H. J., et al. (2022). The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 400( 10352), 563-591. doi:10.1016/S0140-6736(22)01438-6
NLM
Khanh Bao Tran, Lang JJ, Compton K, Xu R, Acheson AR, Henrikson HJ, Kocarnik JM, Penberthy L, Aali A, Alonso N. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019 [Internet]. Lancet. 2022 ; 400( 10352): 563-591.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)01438-6
Vancouver
Khanh Bao Tran, Lang JJ, Compton K, Xu R, Acheson AR, Henrikson HJ, Kocarnik JM, Penberthy L, Aali A, Alonso N. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019 [Internet]. Lancet. 2022 ; 400( 10352): 563-591.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)01438-6
Artigo de periodico
Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021 (2022)
Bollyky, Thomas J; Hulland, Erin N; Barber, Ryan M; Collins, James K; Kiernan, Samantha; Moses, Mark; Pigott, David M; Reiner Junior, Robert C; Sorensen, Reed J. D; Lotufo, Paulo Andrade
Fonte: Lancet. Unidade: FM
Assuntos: COVID-19, FATORES DE RISCO, PAÍSES DESENVOLVIDOS, PAÍSES EM DESENVOLVIMENTO, PNEUMONIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOLLYKY, Thomas J et al. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021. Lancet, v. 399, n. 10334, p. 1489-1512, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00172-6. Acesso em: 30 ago. 2024.
APA
Bollyky, T. J., Hulland, E. N., Barber, R. M., Collins, J. K., Kiernan, S., Moses, M., et al. (2022). Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021. Lancet, 399( 10334), 1489-1512. doi:10.1016/S0140-6736(22)00172-6
NLM
Bollyky TJ, Hulland EN, Barber RM, Collins JK, Kiernan S, Moses M, Pigott DM, Reiner Junior RC, Sorensen RJD, Lotufo PA. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021 [Internet]. Lancet. 2022 ; 399( 10334): 1489-1512.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00172-6
Vancouver
Bollyky TJ, Hulland EN, Barber RM, Collins JK, Kiernan S, Moses M, Pigott DM, Reiner Junior RC, Sorensen RJD, Lotufo PA. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021 [Internet]. Lancet. 2022 ; 399( 10334): 1489-1512.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00172-6
Artigo de periodico
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study (2022)
Tromp, Tycho R.; Hartgers, Merel L. ; Hovingh, G. Kees; Vallejo-vaz, Antonio J. ; Ray, Kausik K.; Soran, Handrean; Freiberger, Tomas; Bertolini, Stefano; Harada-shiba, Mariko; Blom, Dirk J.
Fonte: Lancet. Unidade: FM
Assuntos: ESTUDOS DE COORTES, HIPERCOLESTEROLEMIA, CRIANÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TROMP, Tycho R. et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, v. 399, n. 10326, p. 719-728, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50469. Acesso em: 30 ago. 2024.
APA
Tromp, T. R., Hartgers, M. L., Hovingh, G. K., Vallejo-vaz, A. J., Ray, K. K., Soran, H., et al. (2022). Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, 399( 10326), 719-728. doi:10.1016/S0140-6736(21)02001-8
NLM
Tromp TR, Hartgers ML, Hovingh GK, Vallejo-vaz AJ, Ray KK, Soran H, Freiberger T, Bertolini S, Harada-shiba M, Blom DJ. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study [Internet]. Lancet. 2022 ; 399( 10326): 719-728.[citado 2024 ago. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50469
Vancouver
Tromp TR, Hartgers ML, Hovingh GK, Vallejo-vaz AJ, Ray KK, Soran H, Freiberger T, Bertolini S, Harada-shiba M, Blom DJ. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study [Internet]. Lancet. 2022 ; 399( 10326): 719-728.[citado 2024 ago. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50469
Artigo de periodico
Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020 (2022)
Bryazka, Dana; Reitsma, Marissa B; Griswold, Max G; Abate, Kalkidan Hassen; Abbafati, Cristiana; Kangevari, Mohsen Abbasi; Kangevari, Zeinab Abbasi; Abdoli, Amir; Benseñor, Isabela Judith Martins ; Brunoni, Andre Russowsky
Fonte: Lancet. Unidade: FM
Assuntos: BEBIDAS ALCOÓLICAS, FATORES DE RISCO, DOENÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRYAZKA, Dana et al. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet, v. 400, n. 10347, p. 185-235, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00847-9. Acesso em: 30 ago. 2024.
APA
Bryazka, D., Reitsma, M. B., Griswold, M. G., Abate, K. H., Abbafati, C., Kangevari, M. A., et al. (2022). Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet, 400( 10347), 185-235. doi:10.1016/S0140-6736(22)00847-9
NLM
Bryazka D, Reitsma MB, Griswold MG, Abate KH, Abbafati C, Kangevari MA, Kangevari ZA, Abdoli A, Benseñor IJM, Brunoni AR. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020 [Internet]. Lancet. 2022 ; 400( 10347): 185-235.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00847-9
Vancouver
Bryazka D, Reitsma MB, Griswold MG, Abate KH, Abbafati C, Kangevari MA, Kangevari ZA, Abdoli A, Benseñor IJM, Brunoni AR. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020 [Internet]. Lancet. 2022 ; 400( 10347): 185-235.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00847-9
Artigo de periodico
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) (2022)
Giudice, Linda C; As-sanie, Sawsan; Ferreira, Juan C. Arjona; Becker, Christian M; Abrão, Maurício Simões ; Lessey, Bruce A; Brown, Eric; Dynowski, Krzysztof; Wilk, Krzysztof; Li, Yulan
Fonte: Lancet. Unidade: FM
Assuntos: CO-TERAPIA, GONADOTROFINAS, ENDOMETRIOSE, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUDICE, Linda C et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet, v. 399, n. 10343, p. 2267-2279, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00622-5. Acesso em: 30 ago. 2024.
APA
Giudice, L. C., As-sanie, S., Ferreira, J. C. A., Becker, C. M., Abrão, M. S., Lessey, B. A., et al. (2022). Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet, 399( 10343), 2267-2279. doi:10.1016/S0140-6736(22)00622-5
NLM
Giudice LC, As-sanie S, Ferreira JCA, Becker CM, Abrão MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) [Internet]. Lancet. 2022 ; 399( 10343): 2267-2279.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00622-5
Vancouver
Giudice LC, As-sanie S, Ferreira JCA, Becker CM, Abrão MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) [Internet]. Lancet. 2022 ; 399( 10343): 2267-2279.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00622-5
Artigo de periodico
End compulsory drug treatment in the Asia-Pacific region (2022)
Beyrer, Chris (comentar) ; Paiva, Vera Silvia Facciolla (comentar)
Fonte: Lancet. Unidade: IP
Assuntos: CENTROS DE REABILITAÇÃO, REABILITAÇÃO DA DROGA, DEPENDENTES QUÍMICOS, DIREITOS HUMANOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
End compulsory drug treatment in the Asia-Pacific region. Lancet, v. 29 jan.-4 fe 2022, n. 10323, p. 419-421, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00003-4. Acesso em: 30 ago. 2024.
APA
End compulsory drug treatment in the Asia-Pacific region. (2022). End compulsory drug treatment in the Asia-Pacific region. Lancet, 29 jan.-4 fe 2022( 10323), 419-421. doi:10.1016/S0140-6736(22)00003-4
NLM
End compulsory drug treatment in the Asia-Pacific region [Internet]. Lancet. 2022 ; 29 jan.-4 fe 2022( 10323): 419-421.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00003-4
Vancouver
End compulsory drug treatment in the Asia-Pacific region [Internet]. Lancet. 2022 ; 29 jan.-4 fe 2022( 10323): 419-421.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00003-4
Artigo de periodico
Archbishop Desmond Tutu and the universality of health and human rights (2022)
Beyrer, Chris (comentar) ; Paiva, Vera Silvia Facciolla (comentar)
Fonte: Lancet. Unidade: IP
Assuntos: DESIGUALDADES SOCIAIS, DIREITOS HUMANOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
Archbishop Desmond Tutu and the universality of health and human rights. Lancet, v. 5-11 fe 2022, n. 10324, p. 503-504, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00121-0. Acesso em: 30 ago. 2024.
APA
Archbishop Desmond Tutu and the universality of health and human rights. (2022). Archbishop Desmond Tutu and the universality of health and human rights. Lancet, 5-11 fe 2022( 10324), 503-504. doi:10.1016/S0140-6736(22)00121-0
NLM
Archbishop Desmond Tutu and the universality of health and human rights [Internet]. Lancet. 2022 ; 5-11 fe 2022( 10324): 503-504.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00121-0
Vancouver
Archbishop Desmond Tutu and the universality of health and human rights [Internet]. Lancet. 2022 ; 5-11 fe 2022( 10324): 503-504.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00121-0
Artigo de periodico
Political science and global health policy (2022)
Gómez, Eduardo J; Singh,Prerna; Shiffman, Jeremy ; Barberia, Lorena
Fonte: Lancet. Unidade: FFLCH
Assunto: POLÍTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GÓMEZ, Eduardo J et al. Political science and global health policy. Lancet, v. 399, n. ju 2022, p. 2080-2082, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00923-0. Acesso em: 30 ago. 2024.
APA
Gómez, E. J., Singh, P., Shiffman, J., & Barberia, L. (2022). Political science and global health policy. Lancet, 399( ju 2022), 2080-2082. doi:10.1016/S0140-6736(22)00923-0
NLM
Gómez EJ, Singh P, Shiffman J, Barberia L. Political science and global health policy [Internet]. Lancet. 2022 ; 399( ju 2022): 2080-2082.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00923-0
Vancouver
Gómez EJ, Singh P, Shiffman J, Barberia L. Political science and global health policy [Internet]. Lancet. 2022 ; 399( ju 2022): 2080-2082.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(22)00923-0
Artigo de periodico
Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019 (2021)
Reitsma, Marissa B; Kendrick, Parkes J; Ababneh, Emad; Abbafati, Cristiana; Abbasi-Kangevari, Mohsen; Abdoli, Amir; Benseñor, Isabela Judith Martins ; Brunoni, Andre Russowsky ; Santos, Itamar S
Fonte: Lancet. Unidade: FM
Assuntos: TABAGISMO, PREVALÊNCIA, FATORES DE RISCO, SAÚDE PÚBLICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REITSMA, Marissa B et al. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet, v. 397, n. 10292, p. 2337-2360, 2021Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(21)01169-7. Acesso em: 30 ago. 2024.
APA
Reitsma, M. B., Kendrick, P. J., Ababneh, E., Abbafati, C., Abbasi-Kangevari, M., Abdoli, A., et al. (2021). Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet, 397( 10292), 2337-2360. doi:10.1016/S0140-6736(21)01169-7
NLM
Reitsma MB, Kendrick PJ, Ababneh E, Abbafati C, Abbasi-Kangevari M, Abdoli A, Benseñor IJM, Brunoni AR, Santos IS. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019 [Internet]. Lancet. 2021 ; 397( 10292): 2337-2360.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(21)01169-7
Vancouver
Reitsma MB, Kendrick PJ, Ababneh E, Abbafati C, Abbasi-Kangevari M, Abdoli A, Benseñor IJM, Brunoni AR, Santos IS. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019 [Internet]. Lancet. 2021 ; 397( 10292): 2337-2360.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(21)01169-7
Artigo de periodico
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights (2021)
Beyrer, Chris (comentar) ; Paiva, Vera Silvia Facciolla (comentar)
Fonte: Lancet. Unidade: IP
Assuntos: VACINAÇÃO, COVID-19, DIREITOS HUMANOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights. Lancet, v. 397, n. 10284, p. 1524-1527, 2021Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(21)00708-X. Acesso em: 30 ago. 2024.
APA
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights. (2021). Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights. Lancet, 397( 10284), 1524-1527. doi:10.1016/S0140-6736(21)00708-X
NLM
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights [Internet]. Lancet. 2021 ; 397( 10284): 1524-1527.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(21)00708-X
Vancouver
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights [Internet]. Lancet. 2021 ; 397( 10284): 1524-1527.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(21)00708-X
Artigo de periodico
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants (2021)
Zhou, Bin; Carrillo-Larco, Rodrigo M; Danaei, Goodarz; Riley, Leanne M; Paciorek, Christopher J; Stevens, Gretchen A; Gregg, Edward W; Bennett, James E; Lotufo, Paulo Andrade ; Manitto, Alicia Matijasevich
Fonte: Lancet. Unidade: FM
Assuntos: HIPERTENSÃO, FATORES DE RISCO, ATENÇÃO PRIMÁRIA À SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ZHOU, Bin et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, v. 398, n. 10304, p. 957-980, 2021Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(21)01330-1. Acesso em: 30 ago. 2024.
APA
Zhou, B., Carrillo-Larco, R. M., Danaei, G., Riley, L. M., Paciorek, C. J., Stevens, G. A., et al. (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, 398( 10304), 957-980. doi:10.1016/S0140-6736(21)01330-1
NLM
Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, Gregg EW, Bennett JE, Lotufo PA, Manitto AM. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants [Internet]. Lancet. 2021 ; 398( 10304): 957-980.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(21)01330-1
Vancouver
Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, Gregg EW, Bennett JE, Lotufo PA, Manitto AM. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants [Internet]. Lancet. 2021 ; 398( 10304): 957-980.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(21)01330-1
Artigo de periodico
Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017 (2020)
Reiner Junior, Robert C; Wiens, Kirsten E; Deshpande, Aniruddha; Baumann, Mathew M; Lindstedt, Paulina A; Blacker, Brigette F; Troeger, Christopher E; Earl, Lucas; Munro, Sandra B; Santos, Itamar de Souza
Fonte: Lancet. Unidade: FM
Assuntos: DIARREIA, INCIDÊNCIA, PAÍSES EM DESENVOLVIMENTO, INFERÊNCIA BAYESIANA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REINER JUNIOR, Robert C et al. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017. Lancet, v. 395, n. 10239, p. 1779-1801, 2020Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(20)30114-8. Acesso em: 30 ago. 2024.
APA
Reiner Junior, R. C., Wiens, K. E., Deshpande, A., Baumann, M. M., Lindstedt, P. A., Blacker, B. F., et al. (2020). Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017. Lancet, 395( 10239), 1779-1801. doi:10.1016/S0140-6736(20)30114-8
NLM
Reiner Junior RC, Wiens KE, Deshpande A, Baumann MM, Lindstedt PA, Blacker BF, Troeger CE, Earl L, Munro SB, Santos I de S. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017 [Internet]. Lancet. 2020 ; 395( 10239): 1779-1801.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(20)30114-8
Vancouver
Reiner Junior RC, Wiens KE, Deshpande A, Baumann MM, Lindstedt PA, Blacker BF, Troeger CE, Earl L, Munro SB, Santos I de S. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017 [Internet]. Lancet. 2020 ; 395( 10239): 1779-1801.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(20)30114-8
Artigo de periodico
Attention-deficit hyperactivity disorder (2020)
Posner, Jonathan; Polanczyk, Guilherme Vanoni ; Sonuga-barke, Edmund
Fonte: Lancet. Unidade: FM
Assuntos: TRANSTORNO DO DEFICIT DE ATENÇÃO COM HIPERATIVIDADE, ESTIMULANTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
POSNER, Jonathan e POLANCZYK, Guilherme Vanoni e SONUGA-BARKE, Edmund. Attention-deficit hyperactivity disorder. Lancet, v. 395, n. 10222, p. 450-462, 2020Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)33004-1. Acesso em: 30 ago. 2024.
APA
Posner, J., Polanczyk, G. V., & Sonuga-barke, E. (2020). Attention-deficit hyperactivity disorder. Lancet, 395( 10222), 450-462. doi:10.1016/S0140-6736(19)33004-1
NLM
Posner J, Polanczyk GV, Sonuga-barke E. Attention-deficit hyperactivity disorder [Internet]. Lancet. 2020 ; 395( 10222): 450-462.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(19)33004-1
Vancouver
Posner J, Polanczyk GV, Sonuga-barke E. Attention-deficit hyperactivity disorder [Internet]. Lancet. 2020 ; 395( 10222): 450-462.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(19)33004-1
Artigo de periodico-carta/editorial
Tranexamic acid for traumatic brain injury [Carta] (2020)
Solla, Davi J. Fontoura; Rubiano, Andres Mariano; Teixeira, Manoel Jacobsen ; Andrade, Almir Ferreira de; Paiva, Wellingson Silva
Fonte: Lancet. Unidade: FM
Assuntos: RISCO, COLETA DE DADOS, EFETIVIDADE, HEMATOMA, PESQUISA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOLLA, Davi J. Fontoura et al. Tranexamic acid for traumatic brain injury [Carta]. Lancet. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://observatorio.fm.usp.br/handle/OPI/36906. Acesso em: 30 ago. 2024. , 2020
APA
Solla, D. J. F., Rubiano, A. M., Teixeira, M. J., Andrade, A. F. de, & Paiva, W. S. (2020). Tranexamic acid for traumatic brain injury [Carta]. Lancet. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://observatorio.fm.usp.br/handle/OPI/36906
NLM
Solla DJF, Rubiano AM, Teixeira MJ, Andrade AF de, Paiva WS. Tranexamic acid for traumatic brain injury [Carta] [Internet]. Lancet. 2020 ; 396( 10245): 162-163.[citado 2024 ago. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/36906
Vancouver
Solla DJF, Rubiano AM, Teixeira MJ, Andrade AF de, Paiva WS. Tranexamic acid for traumatic brain injury [Carta] [Internet]. Lancet. 2020 ; 396( 10245): 162-163.[citado 2024 ago. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/36906
Artigo de periodico
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 (2020)
Bikbov, Boris; Purcell, Carrie; Levey, Andrew S; Smith, Mari; Abdoli, Amir; Abebe, Molla; Adebayo, Oladimeji M; Benseñor, Isabela Judith Martins ; Lotufo, Paulo Andrade ; Santos, Itamar de Souza
Fonte: Lancet. Unidade: FM
Assuntos: INFERÊNCIA BAYESIANA, CAUSA DA MORTE, NEFROPATIAS, MORTALIDADE, INSUFICIÊNCIA RENAL CRÔNICA, AVALIAÇÃO DE RISCO, ÁFRICA, ÁSIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BIKBOV, Boris et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, v. 395, n. 10225, p. 709-733, 2020Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(20)30045-3. Acesso em: 30 ago. 2024.
APA
Bikbov, B., Purcell, C., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., et al. (2020). Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 395( 10225), 709-733. doi:10.1016/S0140-6736(20)30045-3
NLM
Bikbov B, Purcell C, Levey AS, Smith M, Abdoli A, Abebe M, Adebayo OM, Benseñor IJM, Lotufo PA, Santos I de S. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Internet]. Lancet. 2020 ; 395( 10225): 709-733.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(20)30045-3
Vancouver
Bikbov B, Purcell C, Levey AS, Smith M, Abdoli A, Abebe M, Adebayo OM, Benseñor IJM, Lotufo PA, Santos I de S. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Internet]. Lancet. 2020 ; 395( 10225): 709-733.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(20)30045-3
Artigo de periodico
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019)
Burtness, Barbara; Harrington, Kevin J; Greil, Richard; Soulieres, Denis; Tahara, Makoto; Castro Junior, Gilberto de Castro ; Psyrri, Amanda; Baste, Neus; Neupane, Prakash; Bratland, Ase
Fonte: Lancet. Unidade: FM
Assuntos: CARCINOMA DE CÉLULAS ESCAMOSAS, NEOPLASIAS DE CABEÇA E PESCOÇO, ANTICORPOS MONOCLONAIS, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BURTNESS, Barbara et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, v. 394, n. 10212, p. 1915-1928, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)32591-7. Acesso em: 30 ago. 2024.
APA
Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 394( 10212), 1915-1928. doi:10.1016/S0140-6736(19)32591-7
NLM
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7
Vancouver
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7
Artigo de periodico
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019)
Mok, Tony S. K; Wu, Yi-Long; Kudaba, Iveta; Kowalski, Dariusz M; Cho, Byoung Chul; Turna, Hande Z; Castro Junior, Gilberto de; Srimuninnimit, Vichien; Laktionov, Konstantin K; Bondarenko, Igor
Fonte: Lancet. Unidade: FM
Assuntos: NEOPLASIAS PULMONARES, IMUNOHISTOQUÍMICA, QUIMIOTERAPIA, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOK, Tony S. K et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, v. 393, n. 10183, p. 1819-1830, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(18)32409-7. Acesso em: 30 ago. 2024.
APA
Mok, T. S. K., Wu, Y. -L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., et al. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 393( 10183), 1819-1830. doi:10.1016/S0140-6736(18)32409-7
NLM
Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro Junior G de, Srimuninnimit V, Laktionov KK, Bondarenko I. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [Internet]. Lancet. 2019 ; 393( 10183): 1819-1830.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(18)32409-7
Vancouver
Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro Junior G de, Srimuninnimit V, Laktionov KK, Bondarenko I. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [Internet]. Lancet. 2019 ; 393( 10183): 1819-1830.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/S0140-6736(18)32409-7

Unidades USP

ReP

Filtros

Unidades USP

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Agência de fomento

Indexado em

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos